Skip to content

Tetraphase (NASDAQ: TTPH), founded in 2006, is a publicly-traded, clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention.

Latest News from Tetraphase Pharmaceuticals